X0306 4 2020-09-08 0001682852 Moderna, Inc. MRNA 0001690927 Zaks Tal Zvi C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 Chief Medical Officer Common Stock 2020-09-08 4 M 0 10000 20.93 A 10000 D Common Stock 2020-09-08 4 M 0 1467 12.21 A 11467 D Common Stock 2020-09-08 4 M 0 5000 14.22 A 16467 D Common Stock 2020-09-08 4 M 0 10000 19.15 A 26467 D Common Stock 2020-09-08 4 S 0 6395 54.69 D 20072 D Common Stock 2020-09-08 4 S 0 8655 55.88 D 11417 D Common Stock 2020-09-08 4 S 0 6457 56.82 D 4960 D Common Stock 2020-09-08 4 S 0 4960 57.88 D 0 D Stock Option (Right to Buy) 20.93 2020-09-08 4 M 0 10000 0 D 2020-03-08 2029-03-08 Common Stock 10000 239195 D Stock Option (Right to Buy) 12.21 2020-09-08 4 M 0 1467 0 D 2027-02-23 Common Stock 1467 22945 D Stock Option (Right to Buy) 14.22 2020-09-08 4 M 0 5000 0 D 2028-02-28 Common Stock 5000 60243 D Stock Option (Right to Buy) 19.15 2020-09-08 4 M 0 10000 0 D 2026-08-10 Common Stock 10000 144790 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.30 to $55.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.36 to $56.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.37 to $57.31. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.39 to $58.28. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. This option is fully vested and exercisable. /s/ Lori Henderson, as Attorney-in-Fact 2020-09-10